VVC Bites
All bites
Sector SignalHealthtech·NotableSignal 48

Global biotech startup funding holds steady at $36B-$40B

Company
Crunchbase
Signal type
Sector Signal
Date
Location
🇺🇸 the US
Sector
Biotech
Investors
Undisclosed

What happened

Global venture funding to biotech startups has maintained between $36 billion and $40 billion annually in recent years, per Crunchbase data. The sector remains on track to match that pace in 2026 despite the surge in AI funding.

Why it matters

Biotech's steady annual capture of $36B to $40B demonstrates resilient institutional capital allocation to life sciences even as generalist venture funds pivot heavily toward generative AI. The sector's specialized investor base and distinct regulatory catalysts insulate it from broader software funding swings.

What to watch

Whether generalist venture funds re-enter early-stage therapeutics rounds or leave the sector predominantly to specialized healthcare firms.

VCBites Signal

57/ 100
Notable signal

Why this score: Sustained annual funding between $36B and $40B shows deep macro stability in life sciences, though static growth prevents a higher signal score.

VCBites' internal significance rating (0-100) — our editorial read, not a market-standard metric. VC Bites' assessment of the significance of this development to the venture ecosystem. Not investment advice.

Who should care?

  • Biotech Founders
  • VC Investors
  • Healthcare Operators
  • LPs

Source

This is an original short summary. Read the full reporting at the original source.

Read the original story on Crunchbase News

Share the signal

VC Bites

Global biotech startup funding holds steady at $36B-$40B

VCBITES SIGNAL: 57 / 100

Why it matters

Biotech's steady annual capture of $36B to $40B demonstrates resilient institutional capital allocation to life sciences even as generalist venture funds pivot heavily toward generative AI. The sector's specialized investor base and distinct regulatory catalysts insulate it from broader software funding swings.

VC Bites · Venture capital signals, explained.

The post text is copied to your clipboard so you can paste it alongside the link.

More Healthtech bites

UndisclosedHealthtechUS·NewNotableSignal 72 · US market

Fortell raises $163M for AI hearing aids

AI hearing aid startup Fortell raised $163 million in new funding. The round included investments from Founders Fund, Thrive Capital, and Valor Equity.

Why it matters

High-conviction backing from Founders Fund and Thrive Capital points to growing venture appetites for consumer medical hardware augmented by AI edge processing. Applying AI to legacy hearing aid tech creates a potential bridge between medical devices and high-margin consumer electronics.

What to watch

Regulatory progress and distribution channels as Fortell transitions from funding to commercial market rollout.

Read biteSource · TechCrunch
UndisclosedHealthtechUS·NewNotableSignal 73 · US market

Fortell raises $163M for AI hearing aids

AI hearing aid startup Fortell raised $163 million in funding. The round included participation from Founders Fund, Thrive Capital, and Valor Equity.

Why it matters

Backing from Founders Fund, Thrive Capital, and Valor Equity for a $163 million round signals strong venture alignment around AI-enhanced medical hardware. Premium software funds entering specialized audio hardware shows appetite for defensible consumer health devices.

What to watch

Track regulatory approvals, manufacturing scaling, and early consumer adoption rates for Fortell's device launch.

Read biteSource · TechCrunch
OtherHealthtechCanada·BackgroundSignal 26 · Canada market

Grey Matters Increases Private Placement to CAD $1.1M

Grey Matters Health Inc. announced an increase and change to its non-brokered equity and convertible debenture private placement to CAD $1.1 million. The Canadian healthcare company is listed on the CSE.

Why it matters

Small-scale equity and convertible debt top-ups on public exchanges like the CSE signal cash preservation over rapid expansion. Micro-placements of this size demonstrate constrained institutional appetite for early-stage public healthtech entities.

What to watch

Conversion terms of the debentures and net cash runway in upcoming filings.

Read biteSource · Financial Post